TY  - JOUR
TT  - PULMONARY RESECTIONS AFTER NEOADJUVANT THERAPY IN PATIENTS WITH PRIMARY LUNG CARCINOMA: RE-EVALUATION OF THE FIRST 90 PATIENTS WITH RECENT EXPERIENCE
AU  - Özkan, Berker
AU  - Kaba, Erkan
AU  - Erus, Suat
AU  - Kapdağlı, Murat
AU  - Ziyade, Sedat
AU  - Tanju, Serhan
AU  - Demir, Adalet
AU  - Dilege, Şükrü
AU  - Toker, Alper
PY  - 2016
DA  - April
DO  - 10.18017/iuitfd.60951
JF  - Journal of Istanbul Faculty of Medicine
JO  - İst Tıp Fak Derg
PB  - Istanbul University
WT  - DergiPark
SN  - 1305-6441
SP  - 1
EP  - 8
VL  - 79
IS  - 1
KW  - Lung cancer
KW  - thoracic surgery
KW  - surgery after neoadjuvant treatment
N2  - Objective: In this study, we aimed to analyse the non-small celllung carcinoma patients who have undergone surgery after neoadjuvantchemo/chemoradiotherapy in regardsto recurrences, survival, complication, morbidity, and mortality.Materials and Methods: The data of 90 patients who had surgeries between June2001 and December 2008 were retropectively evaluated. Fifty nine of those 90patients had neoadjuvant chemotherapy and 31 patients had neoadjuvantchemoradiotherapy. Patients were divided into 3 groups; 47 patients wereclinical T3/N2, 23 patients were clinical T4(N0-1), 20 patients werehistopatologically proven N2(T1-3). Age, gender, tumor pathology, resectiontype, complications, mortality and survival rates of the patients wereevaluated.Results: There were 76 male, 14 female patients in our studygroup. Mean age was 55.3±8.5 (36-75) years. Thirty six patients had lobectomy,11 patients had extended resections with lobectomy, 13 patients had sleevelobectomy, and 30 patients had pneumonectomy operations. Major complication andmortality rates were 14.4% and 2.2% respectively. Minimal and mean follow-upperiods were 24 and 27±18 monthsrespectively. Mean survival was calculated as 25±4.6 months (pathological stageI: 35±9.7 months, stage II: 33±8.5 months, stage IIIa: 24±9.7 months, and stageIIIb: 14±10.9 months). Mean survival was 26±6.7 months in clinical T3/N2 group,14±2.2 months in T4 group, 41±3.7 months in histopathological N2 group. Therewas a statisticaly significant difference in survival times between clinicalT3/N2 and histopathological N2 groups (p<0.05).Conclusion: Lung resections after neoadjuvant therapy can beachieved with acceptable rates of complications, morbidity, and mortality.Surgery in selected patients with proper mediastinal staging may also providelonger survival.
UR  - https://doi.org/10.18017/iuitfd.60951
L1  - https://dergipark.org.tr/en/download/article-file/235442
ER  -